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Abstract
Since 2000, Escherichia coli producing CTX-M enzymes (especially CTX-M-15) have emerged
worldwide as important causes of community-onset urinary tract and blood stream infections due to
extended-spectrum b-lactamase (ESBL) producing bacteria. Studies suggest that the sudden
worldwide increase of CTX-M-15-producing E. coli is mostly due to a single clone named ST131
and that foreign travel to high-risk areas, such as the Indian subcontinent, play in part a role in the
spread of this clone across different continents. Empiric antibiotic coverage for these resistant
organisms should be considered in community patients presenting with sepsis involving the urinary
tract, especially if a patient recently traveled to a high-risk area. If this emerging public health threat is
ignored, it is possible that the medical community may be forced in the near future to use
carbapenems as the first choice for the empirical treatment of serious infections associated with
urinary tract infections originating in the community.
Introduction and context
The extended-spectrum b-lactamases (ESBLs) are a group
of enzymes that have the ability to hydrolyze and cause
resistance to the oxyimino-cephalosporins (cefotaxime,
ceftazidime, ceftriaxone, cefuroxime, and cefepime) and
monobactams (aztreonam), but not the cephamycins
(cefoxitin and cefotetan) or carbapenems (imipenem,
meropenem, doripenem, and ertapenem). These
enzymes are inhibited by the so-called ‘classical’ b-lacta-
mase inhibitors such as clavulanic acid, sulbactam, and
tazobactam [1]. Most ESBLs belong to the class A Ambler
classification system and include the SHV or TEM types
that have evolved from parent enzymes (e.g., TEM-1,
TEM-2, and SHV-1) due to point mutations around the
active site of the b-lactamases. ESBLs are often located
on large plasmids that also harbor genes for resistance
to other antimicrobial classes and, therefore, will often
exhibit multidrug-resistant phenotypes that include
resistance to aminoglycosides and cotrimoxazole [1].
Although ESBLs have been identified in various bacteria,
Klebsiella spp. producing SHV and TEM types of ESBLs
were mostly responsible for serious nosocomial infections
during the 1990s [1]. Specific risk factors included length
of hospital stay, severity of illness, time in the intensive
care unit (ICU), intubations and mechanical ventilation,
urinary or arterial catheterization, and previous exposure
toantibiotics.Mostpatientsinfected withESBL-producing
organisms have been admitted to ICUs, but infections can
also occur in almost any other area of the hospital. These
organisms are also isolated with increasing frequency
from patients in extended-care facilities [2]. Infections
caused by ESBL-producing bacteria are often associated
with increased morbidity, mortality, and health care-
associated costs [3,4]. Organisms producing ESBLs are
clinically relevant and have become important players
among antimicrobial resistant organisms. A report from
IDSA (Infectious Diseases Society of America) from 2006
has listed ESBL-producing Klebsiella spp. and Escherichia
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therapies are urgently needed [5].
Recent advances
The CTX-M-b-lactamases and community onset infections
CTX-M-b-lactamases (which stands for ‘active on Cefo-
TaXime, first isolated in Munich’) were first reported
from Japan in 1986, and during the 1990s occasional
nosocomial outbreaks mostly due to CTX-M-2-produ-
cing Klebsiella pneumoniae were reported from South
America (especially Argentina) [6]. However, since 2000,
E. coli producing CTX-M enzymes have emerged world-
wide as important causes of community-onset urinary
tract infections (UTIs) and bacteraemia, and this
emergence has been referred to as ‘the CTX-M pandemic’
[7]. This is very different from infections caused by
Klebsiella spp. producing TEM- and SHV-derived ESBLs,
which are often limited to nosocomial outbreaks. The
spread of CTX-M enzymes has accelerated rapidly,
especially during the past 5 years, and today b-lactamases
produced by E. coli are the most common types of ESBLs
found in most areas of the world [8].
Risk factors for acquiring community-onset infections
due to CTX-M-producing E. coli include repeat UTIs,
underlying renal pathology, previous antibiotics (includ-
ing cephalosporins and fluoroquinolones), previous
hospitalization, residency in a nursing home , co-morbid
conditions (especially diabetes mellitus and underlying
liver pathology) and international travel [9].
Multidrug resistant CTX-M-15-producing E. coli were first
detected in India during 2001 and have been emerging
worldwide, especially since 2005, as important patho-
gens causing community-onset infections [7,8]. To date,
CTX-M-15 enzymes are the most common and widely
reported type of CTX-M enzyme and have been described
in most countries,including Europe [10], Asia (especially
India) [11], Africa [8], North America [12,13], South
America [14], and Australia [15].
Emergence of multilocus sequencing typing
clone O25:H4-ST131
An identical clone named ST131 has been identified
using multilocus sequencing typing among CTX-M-15-
producing E. coli isolated during 2000 to 2006 from
several countries, including Spain, France, Canada,
Portugal, Switzerland, Lebanon, India, Kuwait, and
Korea [16,17]. Serogroup O25 is associated with this
clone. Clone ST131 belongs to the highly virulent
phylogenetic group B2 and harbors multidrug-resistant
IncFII (incompatibility group FII) plasmids. These initial
studies showed that clone ST131 had emerged indepen-
dently in different parts of the world, spanning three
continents at the same time, suggesting that the
emergence of clone ST131 could be due to either the
ingestion of contaminated food/water sources or impor-
tation into various countries via returning travelers or
both.
Clone ST131 producing CTX-M-15 has also recently been
described in the UK [18], Italy [19], Turkey [20], Croatia
[21], and Japan [22]. CTX-M-15-producing E. coli
belonging to clone ST131 have been identified in isolates
recovered from the community [23], hospitals [24], and
nursing homes settings [25] and, interestingly, also in
companion animals (such as dogs) [26].
Why did CTX-M-15-producing E. coli emerge simulta-
neously in different continents as a cause of community-
onset infections? Recent studies from Calgary, Canada
and Auckland, New Zealand shed some light on this
intriguing question. The publication from New Zealand
describes a series of patients that presented to an
Auckland hospital with community-onset genitourinary
tract infections due to CTX-M-15-producing E. coli that
had a history of travel to, or recent emigration from, the
Indian subcontinent [27]. All the patients lacked the
traditional risk factors associated with UTIs.
A Canadian study demonstrated that travel to the Indian
subcontinent (i.e., India and Pakistan), Africa, and the
Middle East was associated with a high risk of UTI
(including urosepsis) with an ESBL-producing E. coli in
returning travellers [28]. A follow-up study showed that
this high risk of infection was mostly due to the
acquisition of clone ST131 producing CTX-M-15 [29].
A different study from Calgary over an 8-year period
(2000-2007) showed that E. coli clone ST131 producing
CTX-M-15 has emerged as an important cause of
community-onset bacteraemia during the later part of
the study period; 1 of 18 (5%) of ESBL-producing E. coli
isolated from blood between 2000 and 2003 were ST131
as opposed to 20 of 49 (41%) isolated between 2004
and 2007 [30]. In this study, clone ST131 (as compared
to other ESBL-producing E. coli) was more likely to be
resistant to several antibiotics, more likely to produce the
aminoglycoside-modifying enzyme aac(6’)-Ib-cr,a n d
more likely to cause community-acquired infections
and urosepsis. This increase of clone ST131 was also
noted in urine samples from different medical centers in
Canada.
Implications for clinical practice
These studies suggest that the sudden worldwide increase
of CTX-M-15-producing E. coli is due, at least in part, to
clone ST131 and that foreign travel to high-risk areas
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important role in its spread across different continents.
Empiric antibiotic coverage for these resistant organisms
should be considered in community patients presenting
with sepsis involving the urinary and biliary tracts,
especially in areas with a high prevalence of ESBL-
producing E. coli.
The carbapenems such as imipenem, meropenem, and
ertapenem remain the first choice for treatment of
serious infections due to ESBL-producing bacteria.
However, it seems that the quinolones and aminoglyco-
sides might show comparable outcomes if the isolate
tested is susceptible to these agents. Unfortunately,
resistance to these groups is a major concern. Recent
studies have explored the usefulness of alternative
regimens (such as a new cephamycin and ceftazidime
for CTX-Ms) but sufficient clinical data are lacking.
There is a serious need to monitor the spread of this
multidrug resistant clone throughout the world and
there are methods available for the rapid and easy
identification of clone ST131, including repetitive-
element polymerase chain reaction (PCR) typing
schemes [31,32], PCR for the pabB allele [33], PCR for
ST131-associated single-nucleotide polymorphisms in
mdh and gyrB combined with the O25b rfb allele [34] and
a triplex PCR that targets the operon afa FM955459 and
part of the CTX-M-15 gene [35]. If this emerging public
health threat is ignored, it is possible that the medical
community may be forced to use the carbapenems as the
first choice for the empirical treatment of serious
infections associated with UTIs that originate from the
community.
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